Dr. Jaslowski is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1726 Shawano Ave
Green Bay, WI 54303Phone+1 920-884-3135Fax+1 920-884-3144
Education & Training
- San Antonio Uniformed Services Health Education ConsortiumFellowship, Hematology and Medical Oncology, 1990 - 1993
- San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 1987 - 1990
- Loyola University Chicago Stritch School of MedicineClass of 1987
Certifications & Licensure
- MI State Medical License 2001 - 2026
- WI State Medical License 1988 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Fellow (FACP) American College of Physicians, 2000
Clinical Trials
- Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer Start of enrollment: 2005 Jun 01
- Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma Start of enrollment: 2006 Mar 24
- Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer Start of enrollment: 2007 May 01
- Join now to see all
Publications & Presentations
PubMed
- 162 citationsCombination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.Michael B Atkins, Sandra J Lee, Bartosz Chmielowski, Ahmad A Tarhini, Gary I Cohen
Journal of Clinical Oncology. 2023-01-10 - 84 citationsEffect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Random...Thomas E. Stinchcombe, Pasi A. Jänne, Xiaofei Wang, Erin M. Bertino, Jared Weiss
JAMA Oncology. 2019-10-01 - 25 citationsA double-blind, placebo-controlled randomized trial of creatine for the cancer anorexia/weight loss syndrome (N02C4): an Alliance trialAminah Jatoi, Preston D. Steen, Pamela J. Atherton, Dennis F. Moore, Kendrith M. Rowland
Annals of Oncology. 2017-08-01
Press Mentions
- Hats off to Women Helping Cancer ResearchMay 1st, 2017
- ECOG-ACRIN Cancer Research Group Melanoma Research Team Led by Michael Atkins, MD, Receives the 2023 Paper of the Year Distinction from the Journal of Clinical OncologyJanuary 19th, 2024
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: